Focuses on specific molecules or pathways altered in cancer, such as tyrosine kinases, BCL2, or epigenetic regulators. More selective than conventional chemotherapy. Includes monoclonal antibodies and small-molecule inhibitors [56]. The gene discussed is BCL2; the disease is cancer.